RxDoctor Payments Data

Guy Schwartz, MD

Neurology · East Setauket, NYNPI 1265592943

Payments from drug & device makers

$79,110in general payments, 2019–2025

Across 77 payments — averaging $1027.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$50K
  • Ipsen Pharma SAS$25K
  • MDD US Operations, LLC$2K
  • AbbVie$735
  • Medtronic$425
  • Abbott$289
  • plus $315 from 2 others

What the payments were for

  • Consulting fees$2,31055%
  • Travel & lodging$221%
  • Food & beverage$1,80343%
  • Education$401%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sage Therapeutics, LLC1$49,780
Ipsen Pharma SAS15$25,156
MDD US Operations, LLC5$2,410
AbbVie(2 entities)42$735
Medtronic(2 entities)7$425
Abbott3$289
Boston Scientific3$275
Merz North America, Inc.1$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,110 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$405,652
Medicare patients
584
Services billed
30,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl222$682,681
Austedo XrDeutetrabenazine54$554,572
NuplazidPimavanserin Tartrate36$284,888
RytaryCarbidopa/Levodopa103$231,682
NeuproRotigotine59$134,468
Rasagiline Mesylate283$124,731
Tetrabenazine15$43,021
NuedextaDextromethorphan Hbr/Quinidine15$28,899
Carbidopa-LevodopaCarbidopa/Levodopa550$25,471
Carbidopa-Levodopa ErCarbidopa/Levodopa165$14,433
Ropinirole ErRopinirole Hcl31$9,771
AmantadineAmantadine Hcl71$7,695
Selegiline Hcl42$5,904
Rivastigmine15$5,261
Donepezil Hcl217$2,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$2,410$682,681222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →